Company news
Aligos Therapeutics, Inc. news in 2026
Aligos Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
November 6, 2026
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
November 5, 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
October 5, 2026
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
September 2, 2026
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
August 12, 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
July 13, 2026
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
July 6, 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
May 26, 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 13, 2026
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
May 7, 2026
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
April 15, 2026
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
April 13, 2026
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
February 26, 2026
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
February 23, 2026
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 30, 2026
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
January 21, 2026
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
January 13, 2026
Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics
January 8, 2026